RESULTS
pREE
SECONDARY
A total of 172 patients (85 early-PN and 87 late-PN) were included in this secondary analysis, of which 94 were still participating in the study on day 3 and 66 on day 5. For 55 patients (32 early-PN and 23 late-PN), samples were available on all days (admission, day three and five) (Fig. Baseline characteristicsData are no. (%) or median (Q1; Q3). PEPaNIC = Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit; PIM3 = Pediatric Index of Mortality; PN = parenteral nutrition; STRONGkids = Screening Tool for Risk on Nutritional Status and Growth score.Flowchart for inclusion of patients. *Admission (day 0 or 1), day 3, and day 5. PEPaNIC = Early versus Late Parenteral Nutrition in the Pediatric Intensive Care Unit; PN = parenteral nutrition.The course of the biomarkers and ENA for the 55 patients with samples available upon admission, day 3, and 5 are shown in Figure Boxplots for the course of (A) CCK, (B) leptin, (C) glucagon, (D) I-FABP2, (E) citrulline, and (F) enteral intake for patients with samples on all days (n = 55). CCK = cholecystokinin; EN = enteral nutrition; I-FABP2 = intestinal fatty-acid binding protein 2; pREE = predicted resting energy expenditure.The results of the longitudinal analysis regarding the association of biomarkers with ENA in the complete study population (n = 172) are shown in Table The longitudinal associations of %EN of pREE and the biomarkers, corrected for possible confounders, tested with 2-part mixed effects models.The reported coefficients, and the corresponding 95% confidence intervals and FIS occurred in 19 of the 94 patients (20%) on day 3, and in 14 of the 66 patients (21%) on day 5. Patients with FIS had significantly lower CCK concentrations on day 3 than patients without FIS [19.9 pg/mL (14.0; 28.2) vs 30.2 pg/mL (22.2; 40.0), 